Skip to main content
main-content

Oncology

Latest articles

18-04-2019 | Diabetes | News | Article

Study bolsters evidence for 5 alpha-reductase inhibitor link to type 2 diabetes

Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.

18-04-2019 | Oncology | News | Article

68Ga-PSMA-11 PET shows ‘high accuracy’ for localizing recurrent prostate cancer

Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.

17-04-2019 | Oncology | News | Article

Conflicting data reported on immunotherapy benefit for older NSCLC patients

The overall survival benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer is unclear according to two studies with contradictory results presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland.

16-04-2019 | Oncology | News | Article

CheckMate 451: Maintenance immunotherapy fails to improve SCLC survival

Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.

15-04-2019 | Oncology | News | Article

Guidance needed to encourage cancer patients, physicians to discuss CAM use

A third of cancer patients and survivors use complementary and alternative medicine, but they do not always disclose its use to their physicians, findings indicate.

12-04-2019 | Oncology | News | Article

ALK resistance mutations predict lorlatinib efficacy in NSCLC patients progressing on ALK–TKIs

Lorlatinib is more efficacious against non-small-cell lung cancer with versus without ALK resistance mutations in patients with disease progression after at least one second-generation ALK–tyrosine kinase inhibitor, suggests research.

image credits